Pfizer abandons “cholesterol”

After spending tens of $billions in DTC ads and bribes to doctors to terrorize the world into believing that blood “bad cholesterol” is the cause of atherosclerosis, the most common fatal disease, and selling hundreds of $billions worth of Lipitor to lower it, Pfizer has admitted there is no truth to and no more profit to be made from the myth of “dyslipidemia” that Pfizer and other peddlers of statin drugs created. Its much hyped drug, torceptripib, touted as the next Lipitor, which did all the “right” things to blood cholesterol actually worsened atherosclerosis in the ILLUSTRATE trial. Finally, the proof was in that high blood “bad cholesterol” is only a symptom of an atherogenic lifestyle, not the cause of atherosclerosis. But it will take a generation or two for the cholesterol myth to disappear.

So now Pfizer is directing more of its research toward Type 2 diabetes, a disease directly related to obesity, which is directly related to the moral hazard effect created by the cholesterol myth (I can eat anything as long as my cholesterol is low). Very clever marketing! Create diseases, real or imagined, then sell high profit drugs to to “treat” numbers associated with them.

---

PFIZER REFOCUSES ITS STRATEGY
BY SHANNON PETTYPIECE Bloomberg News
National Post
01 Oct 2008

Pfizer Inc. will abandon early-stage research on heart drugs as part of a strategy to sharpen its focus on ailments such as cancer, Alzheimer’s disease and diabetes where the chances of a bigger profit are greatest. The New York-based company, the…read more…

Tech Tags: National Post newspaper Financial Post

ILLUSTRATE illustrates the futility of measuring and treating blood “cholesterol”

Intravascular ultrasound is a sensitive method for measuring the size of atherosclerotic plaques in the arterial wall. When testing a drug to see if it will have an effect on plaque volume, this technique is the gold standard.

ILLUSTRATE set out to show that adding torcetrapib, a drug that increases HDL, the “good” cholesterol, to Lipitor, that decreases, LDL, “bad” cholesterol would reverse plaque or at least stop its progression.

Here are the baseline characteristics of the subjects. Note that the average BMI was 30. Overweight is defined as a BMI over 25 and obesity over 30. So, all of them were overweight or obese. 20% were diabetic, most likely Type 2, related to obesity, and 75% were hypertensive. 18% smoked. All of those factors are risk factors for atherosclerosis related to lifestyle. Therefore, unless one intends to first completely eliminate these lifestyle risk factors, it was unethical to even conceive such a trial particularly since it is proven that atherosclerosis can be reversed by lifestyle change alone. The trialists probably rationalized that atherosclerosis, like pneumonia, must be treatable by drugs and Pfizer, who funded the trial, has a slogan, “Working for a Healthier World” it is ethical to do such a trial. Besides the money helps to keep one’s IVUS lab going and one is promoting the notion that the technique will some day lead to the cure for atherosclerosis.

 

The typical ILLUSTRATE patient

Here are the reported results. What was not mentioned in the abstract above is that plaque actually INCREASED in both the the Lipitor only group and the Lipitor plus torcetrapib group. Now, before actually starting the trial, the subjects were given enough Lipitor to adhere to the guidelines written by doctors paid by Pfizer and other statin dealers. So, following the guidelines for blood cholesterol lowering with Lipitor does not slow progression of plaque. The obsession with blood cholesterol is completely futile.

nejm-illustrate-result.jpg

The conclusions of the authors shows their blinkered view of atherosclerosis. While Dr. Nissen donates his personal drug money to charity (how much is paid to run his IVUS lab, if any, is not stated), all the other authors have major financial connections to drug dealers. Revkin, Shear and Duggan are employees of Pfizer and own stock. Naturally this group would ignore non-drug methods for reversing atherosclerosis

We have known how to reverse the atherosclerotic process very easily since the revolutionary work of Dean Ornish the final report of which was published in 1998. No drugs are necessary, only a change in lifestyle which was not seriously attempted in this study. There is even no reference to Ornish’s work in the paper, a major oversight of the reviewers. So, why don’t the IVUS groups do a study of plaque volume after significant lifestyle change? Who would fund it? If Pfizer is really “Working for a Healthier World” and not just making a profit, Pfizer should be funding an IVUS lifestyle trial.